MBIO vs. GNPX, MEIP, UBX, NXTC, BYSI, SLS, ENLV, NBRV, ENOB, and RAIN
Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Genprex (GNPX), MEI Pharma (MEIP), Unity Biotechnology (UBX), NextCure (NXTC), BeyondSpring (BYSI), SELLAS Life Sciences Group (SLS), Enlivex Therapeutics (ENLV), Nabriva Therapeutics (NBRV), Enochian Biosciences (ENOB), and Rain Oncology (RAIN). These companies are all part of the "pharmaceutical preparations" industry.
Mustang Bio vs.
Mustang Bio (NASDAQ:MBIO) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Genprex's return on equity of -109.81% beat Mustang Bio's return on equity.
Mustang Bio has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Genprex has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500.
13.7% of Mustang Bio shares are held by institutional investors. Comparatively, 9.1% of Genprex shares are held by institutional investors. 2.1% of Mustang Bio shares are held by company insiders. Comparatively, 12.0% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Genprex received 30 more outperform votes than Mustang Bio when rated by MarketBeat users. Likewise, 64.90% of users gave Genprex an outperform vote while only 64.34% of users gave Mustang Bio an outperform vote.
In the previous week, Genprex had 6 more articles in the media than Mustang Bio. MarketBeat recorded 7 mentions for Genprex and 1 mentions for Mustang Bio. Genprex's average media sentiment score of 0.86 beat Mustang Bio's score of 0.00 indicating that Genprex is being referred to more favorably in the news media.
Mustang Bio currently has a consensus price target of $43.33, suggesting a potential upside of 609.22%. Genprex has a consensus price target of $3.00, suggesting a potential upside of 212.50%. Given Mustang Bio's higher probable upside, analysts clearly believe Mustang Bio is more favorable than Genprex.
Summary
Genprex beats Mustang Bio on 7 of the 12 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mustang Bio Competitors List
Related Companies and Tools
